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Traumatic brain injury (TBI) is one of the leading causes of disability in the United States. The EKSO GT
Bionics® (EKSO®) is a robotic exoskeleton approved by the Federal Drug Administration (FDA) for
rehabilitation following a cerebrovascular accident (CVA or stroke) and recently received approval for use
in patients with TBI. The aim of the study was to examine if the use of exoskeleton rehabilitation in
patients with TBI will produce bene cial outcomes.
Methods
This retrospective chart-review reports the use of the (EKSO®) robotic device in the rehabilitation of
patients with TBI compared to patients with CVA. We utilized data from a single, private rehabilitation
hospital for patients that received post-CVA or post-TBI robotic exoskeleton intervention. All patients that
used the exoskeleton were discharged from the hospital between 01/01/2017 to 04/30/2020. Ninety-four
percent of patients in the CVA groups and 100% of patients in the TBI group were of Hispanic or Latino
ethnicity. Gains in total Functional Independence Measure (FIM), walking and cognition, and length of
stay in the rehabilitation facility were measured.
Results
Patients in the TBI group (n = 11) were signi cantly younger than the patients in the CVA group (n = 66; p 
< 0.05). Both groups spent a similar amount of time active, number of steps taken, and the number of
sessions in the exoskeleton. Both groups also started with similar admission FIM scores. The FIM gain in
the TBI group was similar to that of the CVA group (37.5 and 32.0 respectively). The length of stay
between groups was not different either.
Conclusions
The use of exoskeleton rehabilitation in patients with TBI appear to produce similar outcomes as for
patients with CVA, prompting further attention of this intervention for this type of injury. Trial registration:
Retrospectively registered on 07/09/2020 in clinicaltrials.gov number NCT4465019.
Introduction
Traumatic brain injury (TBI) is one of the leading causes of disability in the United States. According to
the Centers for Disease Control, approximately 3.2 to 5.3 million people are living with a TBI related
disability in the United States1. Three speci c age groups show a high risk of TBI: children aged 0–4,
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adolescents between 15–19 years of age, and adults 75 years and older 2. The two leading causes of TBI
are motor vehicle accidents and falls3,4. While the number of TBI related emergency department visits in
the United States has increased by 54% from 2006–2014, the mortality from TBI has decreased over the
same time period4, suggestive of the positive impact of rehabilitation services. Severe to moderate TBI
has the potential to create motor and ambulation de cits, which may resemble those presented in
cerebrovascular accidents (CVA or stroke)5. Early intervention following TBI has been shown to produce
improvements in post-TBI symptomathology6.
The bene cial use of robotic rehabilitation following a CVA has been long established in the  eld. The
 rst studies that examined the acceptance of robotics in patients after CVA started in the nineties7.
Consensus suggests that robotic-assisted gait training in patients after suffering a CVA or stroke is more
likely to recover independent walking compared to those who did not use the robotic devices8,9. Studies
also suggest that the use of robotics in rehabilitation could not only result in motor stills improvement but
also transfer into other domains of daily living that require similar activities10, hence improving cognitive
domains.
The use of robotics in rehabilitation medicine has become more popular due to the advantages it
provides to the patients and the providers. The EKSO GT Bionics® (EKSO®; Richmond, California, USA) is
a robotic exoskeleton approved by the Federal Drug Administration (FDA) for rehabilitation following
spinal cord injury, stroke, and recently received approval for acquired brain injury (including TBI)11. The
use of this device provides an advantage to patients with these types of injuries by assisting them in
walking with at least 3/5 arm and upper muscle strength. It also provides a variable amount of power
assistance to bilateral lower extremities and the ability for clinicians to control the device. EKSO® is
approved for spinal cord injury up to C7 complete, any level of incomplete spinal cord injury, and
hemiplegia due to stroke. The use of EKSO® in the rehabilitation of patients with TBI is starting to
emerge due to the similarity of stroke-related impairments that can bene t from exoskeleton intervention.
A recent case report of a young adult who suffered TBI, which resulted in right-side hemiplegia, revealed
that the use of the EKSO® during a 4-week inpatient program signi cantly improved motor functional
independence measure FIM score from admission to discharge12.
Not all patients are candidates for EKSO®-driven rehabilitation. All available bionic exoskeletons currently
in the market have weight and height requirements as well as a set of contraindications for its use to
ensure patient safety13. For example, bone mineral density is a metric for eligibility as to reduce the risk
of fracture while using the device 14. Moreover, the decision to employ bionic devices in a patient
rehabilitation program is weighed by both provider recommendations and patient preferences. While
some studies in patients with spinal cord injury and stroke demonstrate bene ts from the use of
exoskeletons, additional evidence for disorders that cause gait and mobility problems such as TBI are still
necessary15,16.
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The main goal of our study was to examine the preliminary evidence of any bene cial outcomes,
gathered at a single site-rehabilitation hospital using the EKSO® in a cohort of patients who suffered TBI
compared to patients who suffered a CVA. We compared our cohort of patients with TBI with all available
data of patients with CVA who used the exoskeleton. Parameters used were the change (from admission
to discharge) in total functional independence measure FIM, walking FIM gain, length of stay in the
rehabilitation facility as well as cognitive FIM gain. Our central hypothesis was that the use of EKSO®
improved function for TBI regardless of injury mechanism, similar to patients who suffered CVA and were
also rehabilitated using the EKSO®. This hypothesis was based on the rationale that TBI and CVA
produce related neurofunctional impairments17,18. To the best of our knowledge, this is the  rst study to
analyze and report the use of the EKSO® in patients who suffered TBI. This study is also the  rst to
report the outcomes of EKSO® use in a cohort of mostly Hispanic ethnicity patients.
Methods
Study Design and Setting
This is an observational, retrospective, chart review cohort study of patients from a private single
rehabilitation hospital. Study approval was granted by the local Institutional Review Board and
conformed to the Declaration of Helsinki and the US Federal Policy for the Protection of Human Subjects.
Due to the retrospective nature of the study, a full waiver of authorization under the Health Insurance
Portability and Accountability Act (1996) was submitted by the study team and approved by the
Institutional Review Board.
Participants
Inclusion and Exclusion criteria
Subjects in the TBI group included patients who suffered a TBI and who used the EKSO® bionic
exoskeleton during their rehabilitation treatment from 01/01/2017 to 04/30/2020. Subjects in the CVA
group included all patients in the hospital that used the EKSO® during their rehabilitation process during
the same period of the patients in the TBI group. Patients were excluded if their injury type was outside
the scope of the current study. The registered nurse at the rehabilitation facility identi ed the patients
based on the inclusion criteria, and this was veri ed by the doctor in physical therapy who oversees the
rehabilitation hospital patient population. Approval and implementation of the EKSO® bionic device at
the hospital commenced in 2014 for patients that suffered a CVA and spinal cord injury. Main indications
for the use of the EKSO® during rehabilitation included a height range between 1.56 to 1.9 meters and a
patient's weight equal to or less than 100 kg. Stable blood pressure was required, with the ability to follow
one to two steps commands, and the patient should also have demonstrated a normal range of motion in
hips, knees, and ankles.
Variables
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Demographic factors considered in this study were age at the time of admission into the rehabilitation
facility (measured in years), and patient's sex (males or females). Ethnicity was self-reported and
collected in the study, but it was not considered as a covariate since the vast majority of our cohort was
of Hispanic origin. The overrepresentation of Hispanics/Latinos in the current cohort responds to the
demographic distribution of the area the hospital serves. We collected information related to the
impairment type produced by the CVA, and for the TBI, we collected the abbreviated injury scale (ASI) to
determine the injury severity score (ISS).
The change in FIM score from admission to discharge was used as the primary outcome for this study.
The FIM score evaluates the ability of the patient in day-to-day functions within three (3) major
categories: self-care, mobility, and communication. To explore whether the use of EKSO® facilitates the
improvement in mobility and communication, we also explored the motor FIM and social interaction FIM,
problem-solving FIM, and memory FIM. In parallel to FIM, we evaluated how the length of stay in the
facility affected the outcomes.
Data sources/measurements
Variables collected in this study were retrospectively obtained from the patient's electronic medical chart.
All information presented in this study was part of the patient’s standard of care. No additional
intervention or data collection instrument was implemented. The standard of care of the patient is as
follows: all potentially eligible candidates were identi ed and cleared by the physician with subsequent
patient education regarding the use of the EKSO®. For the use of the exoskeleton during the rehabilitation
process, signed informed consent was obtained from either the patient or designated family member,
depending on the status of the patient. Data obtained during the active use of the exoskeleton was
visualized in the screen of the EKSO® (time active, steps taken, etc.) and subsequently recorded in each
patient’s paper chart. This paper was then scanned and uploaded into the patient’s electronic chart under
his/her progress notes. The therapy technicians helped in the data recording process. All available data
related to EKSO use for CVA and TBI at our facility were included in the current study. The primary goal of
the data analysis was to gather preliminary comparative outcomes that could guide us into designing
larger-controlled studies.
Reduction of Bias
To minimize selection bias in the current study, we used all patients that were clinically determined by the
attending physician to meet the criteria for exoskeleton rehabilitation. Patients were included in the chart
review regardless of the number of sessions of exoskeleton use. All therapist and nurses at our facility
have been certi ed to use the FIM assessment tool and the data is entered using the Uniform Data
System for Medical Rehabilitation (https://www.udsmr.org/) software integrated within the hospital
medical record platform. The main data extractor in the study (A.M.) is the site expert for data
management within the Uniform Data System. Quality of the data was veri ed by the lead doctor in
Physical Therapy (M.E.A.). None of the patients that used exoskeleton in rehabilitation had missing data
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during the time period used for the current study and all patients in the cohort completed the
recommended therapeutic program and were successfully discharged from the hospital.
Exoskeleton use protocol
The EKSO GT® was operated by a Licensed Physical Therapist who was certi ed to control the device.
The device is only approved to be used in a clinical setting. For the purposes of this study, four different
modes were utilized to engage and challenge the patients: Pre-Gait, First Step, Pro Step Plus, and 2 Free.
Pre-Gait Mode focused on the following metrics to facilitate movement and active participation: bilateral
weight shifting in standing with biofeedback, mini squats, and stationary unilateral lower extremity
advancement. The First Step mode allowed the therapist to be in full control of all movement. The
therapist triggered the initiation and execution of each step reciprocally with the push of a button. In the
Pro Step Plus mode, there was an appropriate weight shift either done independently by the patient or
facilitated by the therapeutic handling of the physical therapist. The patient was given the opportunity to
initiate each step; the EKSO® device completed any incomplete steps. The most advanced mode is called
2 Free. This mode was used to challenge the patient across the continuum as they progress. The patient
was responsible for initiating and executing each step. The therapist programmed resistance unilaterally
or bilaterally to the lower extremities to increase the demand for the activity.
Statistical methods
Descriptive statistics for the entire study population were generated. Normally distributed continuous
variables were described with means and standard deviations, medians and ranges were used for non-
normally distributed variables, and frequencies and column percentages summarized categorical
variables. Differences in demographic and clinical characteristics between the two treatment groups were
evaluated using Student t-test for independent samples for normally distributed continuous variables,
Mann-Whitney U test for non-normally distributed continuous variables, and Fisher exact test for
categorical variables. To test for the difference between the CVA and TBI groups in respect to socio-
demographic and treatment measurements, paired t-test or Wilcoxon signed-rank test for continuous
variables and Chi-square test/Fisher exact test for categorical variables were used. Shapiro-Wilk test for
normality was conducted to determine the normality of the continuous variables' distributions. Linear
regression analyses were carried out to evaluate the associations of each of the outcome variables with
age, sex, and length of hospital stay, and with the injury groups (CVA and TBI) variable. All statistical tests
were two-sided and were performed at a signi cance level of 0.05. All statistical analyses were conducted
using SAS 9.4 (SAS Institute, Inc, Cary, North Carolina, USA.).
Results
Participants
From January 1st, 2017 to April 30th, 2020, rehabilitation was provided for 619 patients with CVA and
140 with TBI. A total of 66 (10.7%) and 11 (7.9%) patients met the criteria and agreed to use the
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exoskeleton for CVA and TBI respectively. All but one patient that used the exoskeleton during the
retrospective review period were included in the study. This patient was excluded from the TBI group
during the data quality review process since the exoskeleton was not used for gait therapeutic purpose,
but solely as a tool to increase arousal in the individual.
Outcome Analysis
Patients who suffered TBI and used the exoskeleton for rehabilitation had a mean age of 45 ± 25.81,
while patients who suffered CVA and used the exoskeleton had a mean age of 62.7 ± 12.76. Males were
predominant (77.9%) in the entire study population. Bivariate analyses showed that patients in the TBI
group were signi cantly (p < 0.05) younger than patients in the CVA group (Table 1). The mean number of
exoskeleton training sessions was similar between groups with 3.5 ± 1.86 sessions in the TBI group and
3.5 ± 2.93 sessions in the CVA. Similarly, both groups spent equal amount of mobile minutes and took a
similar amount of steps in the exoskeleton (Table 2). Average ISS for patients with TBI was 11 ± 14.7
points. In the CVA group, 33 patients had an impairment coded as 1.1 (stroke with left body involvement),
31 patients had an impairment code of 1.2 (stroke with right body involvement), and two patients were
coded as 1.3 (stroke with bilateral involvement).
Further bivariate analyses revealed that none of the continuous variables measured were signi cantly
different between groups (Table 2). On average, both groups had a similar number of exoskeleton
rehabilitation sessions, minutes and steps taken during the sessions. The length of stay (LOS) and the
length of stay e ciency (LSE) were also similar for both groups. The overall admission FIM rating was
taken into consideration as a baseline measurement, showing a similar level of function between groups
(Table 2). When comparing the change in overall FIM, the TBI group scored 5.5 points higher than the CVA
group but there was no signi cant difference in this measurement. Similarly, the TBI group had a score
that was 4.5 points over the CVA group for motor FIM change, but not signi cantly different. All three
cognitive domains for FIM, memory, problem solving and social interaction scored similarly between
groups during admission, discharge and overall change (Table 2).
Linear regression analyses demonstrated that there were no signi cant correlations of age with any of
the FIM scores quanti ed or the length of stay.
Discussion
We present a comparative analysis amongst patients with a history of CVA and TBI, showing similar
outcomes regardless of the injury type. Both CVA and TBI are non-progressive central nervous system
condition that have very similar impairments19. Because of the similarity in impairment between CVA and
TBI, the use of exoskeleton rehabilitation for TBI patients was conceivable. While it is recognized that
additional controlled clinical trials are needed for exoskeleton rehabilitation in TBI, this preliminary study
illustrates similar, positive outcomes in functionality to those patients treated with the exoskeleton which
had a CVA.
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Patients within the TBI group were signi cantly younger than patients in the CVA group. There are several
possible explanations for this observation. First, more than 80% of all stroke incidences across the nation
occur in people 65 years and older20, in comparison to TBI for which two of the high risk groups are
young children (age 0 to 4) and older adolescents (age 15 to 19; 1). Second, the use of the EKSO®
required speci c physical (e.g., height and weight) characteristics as well as physiological (e.g., bone
density) to prevent injuries. It is well documented that older patients (> 50 years of age) are at higher risk
of osteoporosis 21, which is one of the main contraindications for the use of the exoskeleton, excluding
them as potential users. Patient-preference is held at the highest priority when identifying eligible users.
Anecdotal evidence from our hospital suggests that older patients are less likely to prefer rehabilitation
with the exoskeleton, while younger patients are more eager to engage in the use of bionics and robotics,
which could partially explain the age difference in our cohort of patients. Additional studies are needed to
explore the generational gap in rehabilitation preferences, especially for the use of robotic devices.
Patients who suffer TBI, even when mild, could end up having impairments up to one year post injury 22.
Cognitive impairments after TBI could have even a longer sequelae, lasting up to 4 years, as previously
reported 23. The sequelae post-TBI that affects cognitive function is known as postconcussive
syndrome24. To minimize its impact in patient’s quality of life, rehabilitation approaches that promote
neuroplastic changes in the brain, such as those produced by exoskeleton training, could result in an
overall increase in functional domains for the patient after a TBI or CVA 25. While the overall improvement
in cognitive FIM scores in the current cohort of patients was small, a 1 point increase in FIM scores
corresponds to an increase of 1.08 more likely to be discharged to the home rather than to
institutionalized care26; hence decreasing healthcare cost on the long-term.
The use of robotic interventions in patients with TBI has lagged behind in comparison to the stroke  eld.
A systematic review from 2011 reported ten randomized controlled trials for the use of robotic devices in
CVA rehabilitation, but none for TBI 27. However, recent reports indicate increased use of robotic
rehabilitation following TBI; for example, to quantify the degree of impairment 28, improve cognitive
function29, to support treadmill training30, to measure brain activity while having robotic gait training31,
and to increase gait velocity32. While the outcomes of these studies are mixed due to the differences in
patient population, training techniques used, and type of equipment, it is promising that the  eld is
recognizing how robotics present with a novel opportunity to improve quality of life in patients with TBI.
A recent study exploring the longitudinal effects of TBI revealed that higher total health burden was
associated with poorer functional motor and cognitive trajectories33. To decrease the negative impact
that TBI might have, it is hypothesized the continuous use of EKSO® as a rehabilitation device in our
hospital will signi cantly continue to improve functional outcomes. Since the intervention with EKSO®
revealed similar outcomes to the CVA patient cohort, even with small sample size, it is foreseen that many




The literature on the use of exoskeleton devices for TBI resoundingly contains the limitation of sample
size 15, which restricts the power of the study to derive any reasonable outcomes. However, the limitation
in the selection of a statistically signi cant sample size corresponds to the fact that patients need to
meet a speci c set of criteria to be eligible for rehabilitation with exoskeleton devices, as outlined in the
methods section. It is also important to recognize that our study is based on a retrospective sample of
patients, most of which were of Hispanic origin; thus, generalization to other ethnic groups might be
limited. An additional consideration in this analysis was the fact that we did not control for comorbidities.
While individual comorbidities may not directly affect outcomes observed in the use of exoskeleton,
chronic conditions such as pressure sores, spinal instability, deep vein thrombosis, uncontrolled
hypertension, among others 13 are direct contraindications for the use of the device; hence limiting the
pool of patients that can be included in the research studies. We did not control for severity of injury in
the patients. However, our patients started with similar admission FIM scores, allowing us to have a
similar baseline. Well-controlled randomized trials on exoskeleton rehabilitation are emerging as per
published protocols 34.
Conclusions
Physical therapists are more frequently employing robotic technology to enhance traditional
rehabilitation therapy methods. The use of robotic technology to more speci cally and deliberately treat
patients with brain insults is allowing for increased intensity and duration of activity, and engagement of
the patient with an activity of interest. This study demonstrated that gait training with the EKSO® GT
Robotic Exoskeleton in patients with TBI as compared with a cohort of patients with CVA leads to similar
improvements on FIM scores. Large multicenter randomized controlled trials comparing the use of the
exoskeletons vs. traditional methods in the TBI population are warranted to verify and expand the
















Ethical Approval and Consent to Participate
Study approval was granted by the DHR Health Institute for Research and Development Institutional
Review Board and conformed to the Declaration of Helsinki and the US Federal Policy for the Protection
of Human Subjects.  Due to the retrospective nature of the study, a full waiver of authorization under the
Health Insurance Portability and Accountability Act (1996) was submitted by the study team and
approved by the Institutional Review Board. 
Consent for Publication
All authors reviewed and approved the current version of the manuscript for publication. 
Availability of Supporting Data
The datasets used and analyzed during the current study are available from the corresponding author on
reasonable request.
            Competing Interests
The following authors are employees of DHR Health System: LTR, MEA, AM, SV and ATR.  Authors declare
no other con icts of interest and have no relationship of consulting employment or funding with the
manufacturers of the devices used in the current study. None of the authors holds shares or stocks with
EKSO Bionics Holdings.
Funding
Theresearch work presented received no funding by either the participating institutions or external
sources.
            Authors Contributions
LTR, MER and AM were responsible for the design of the study, data analysis and interpretation, and
provided scienti c content to the article.  In addition, AM and MEAcollected the data.  KV was responsible
for data analysis and provided scienti c and grammatical revisions to the manuscript.  LMA was
responsible for the scienti c literature search and wrote the  rst draft of the Introduction.  SV provided
interpretation to the data and revision to the manuscript. ATR was responsible for the literature search,
interpreted the statistical analyses, helped draft the manuscript results and discussion, and was
responsible for the distribution and  nal approval by all authors. 
            Acknowledgements
Page 11/15
We appreciate the helpful review of an earlier version of this manuscript by Dr. Sohail Rao from DHR
Health Institute for Research and Development.
            Author’s information
Authors e-mails in the same order of authorship: lis.trevino@dhr-rgv.com, kristina.vatcheva@utrgv.edu,
m.auer@dhr-rgv.com, an.morales@dhr-rgv.com, lama.abdurrahman01@utrgv.edu, s.viswanitra@dhr-
rgv.com, anne.torres@dhr-rgv.com
References
1. Centers for Disease Control and Prevention. Report to Congress on Traumatic Brain Injury in the
United States: Epidemiology and Rehabilitation. Atlanta, GA; 2015. doi:10.3171/2011.3.jns102010.
2. Faul M, Coronado V. Epidemiology of Traumatic Brain Injury. Vol 127.; 2015. doi:10.1016/B978-0-
444-52892-6.00001-5.
3. National Spinal Cord Injury Statistical Center. Facts and Figures at Glance. Birmingham, AL; 2019.
4. Centers for Disease Control and Prevention. Surveillance Report of Traumatic Brain Injury-Related
Emergency Department Visits, Hospitalizations, and Deaths. United States; 2019.
https://www.cdc.gov/traumaticbraininjury/get_the_facts.html.
5. Williams G, Lai D, Schache A, Morris ME. Classi cation of gait disorders following traumatic brain
injury. J Head Trauma Rehabil. 2015;30(2):E13–23. doi:10.1097/HTR.0000000000000038.
6. Parrington L, Jehu DA, Fino PC, et al. The Sensor Technology and Rehabilitative Timing (START)
Protocol: A Randomized Controlled Trial for the Rehabilitation of Mild Traumatic Brain Injury. Phys
Ther. January 2020. doi:10.1093/ptj/pzaa007.
7. Dijkers MP, deBear PC, Erlandson RF, Kristy K, Geer DM, Nichols A. Patient and staff acceptance of
robotic technology in occupational therapy: a pilot study. J Rehabil Res Dev. 1991;28(2):33–44.
doi:10.1682/jrrd.1991.04.0033.
8. Mehrholz J, Thomas S, Werner C, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for
walking after stroke. Cochrane database Syst Rev. 2017;5(5):CD006185.
doi:10.1002/14651858.CD006185.pub4.
9. Bruni MF, Melegari C, De Cola MC, Bramanti A, Bramanti P, Calabrò RS. What does best evidence tell
us about robotic gait rehabilitation in stroke patients: A systematic review and meta-analysis. J Clin
Neurosci Off J Neurosurg Soc Australas. 2018;48:11–7. doi:10.1016/j.jocn.2017.10.048.
10. Fasoli SE, Adans-Dester CP. A Paradigm Shift: Rehabilitation Robotics, Cognitive Skills Training, and
Function After Stroke. Front Neurol. 2019;10:1088. doi:10.3389/fneur.2019.01088.
11. Globe Newswire. Ekso Bionics® Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton
for Use with Acquired Brain Injury Patients.https://www.globenewswire.com/news-
release/2020/06/25/2053400/0/en/Ekso-Bionics-Receives-FDA-Clearance-to-Market-its-EksoNR-
Robotic-Exoskeleton-for-Use-with-Acquired-Brain-Injury-Patients.html. Published June 25, 2020.
Page 12/15
12. 10.1109/EMBC.2018.8512745
Nolan KJ, Karunakaran KK, Ehrenberg N, Kesten AG. Robotic Exoskeleton Gait Training for Inpatient
Rehabilitation in a Young Adult with Traumatic Brain Injury. Conf Proc. Annu Int Conf IEEE Eng Med
Biol Soc IEEE Eng Med Biol Soc Annu Conf. 2018;2018:2809–2812.
doi:10.1109/EMBC.2018.8512745.
13. Palermo AE, Maher JL, Baunsgaard CB, Nash MS. Clinician-focused overview of bionic exoskeleton
use after spinal cord injury. Top Spinal Cord Inj Rehabil. 2017;23(3):234–44. doi:10.1310/sci2303-
234.
14. Asselin PK, Avedissian M, Knezevic S, Kornfeld S, Spungen AM. Training Persons with Spinal Cord
Injury to Ambulate Using a Powered Exoskeleton. J Vis Exp. 2016;(112). doi:10.3791/54071.
15. Dijkers MP, Akers KG, Dieffenbach S, Galen SS. Systematic Reviews of Clinical Bene ts of
Exoskeleton Use for Gait and Mobility in Neurologic Disorders: A Tertiary Study. Arch Phys Med
Rehabil. 2019. doi:10.1016/j.apmr.2019.01.025.
16. Hesse S, Werner C. Connecting research to the needs of patients and clinicians. Brain Res Bull.
2009;78(1):26–34. doi:10.1016/j.brainresbull.2008.06.004.
17. Giles GM. Cognitive Versus Functional Approaches to Rehabilitation After Traumatic Brain Injury:
Commentary on a Randomized Controlled Trial. Am J Ocupational Ther. 2010;64(May):182–5.
doi:10.5014/ajot.64.1.182.
18. Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic Brain Injury: An Overview of Epidemiology,
Pathophysiology, and Medical Management. Med Clin North Am. 2020;104(2):213–38.
doi:10.1016/j.mcna.2019.11.001.
19. DiRocco PJ. Fitness Programming and Physical Disability. 1st ed. (Miller PD, editor). Champaing:
Human Kinetics; 1995.
20. Blackwell DL, Villarroel MA. Summary Health Statistics for U.S. adults: National health interview
survey. National Center for Health Statistics. . Published 2018.
21. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194(2
Suppl):3–11. doi:10.1016/j.ajog.2005.08.047.
22. Nelson LD, Temkin NR, Dikmen S, et al. Recovery After Mild Traumatic Brain Injury in Patients
Presenting to US Level I Trauma Centers: A Transforming Research and Clinical Knowledge in
Traumatic Brain Injury (TRACK-TBI) Study. JAMA Neurol. 2019;76(9):1049–59.
doi:10.1001/jamaneurol.2019.1313.
23. Theadom A, McDonald S, Starkey N, et al. Social cognition four years after mild-TBI: An age-matched
prospective longitudinal cohort study. Neuropsychology. 2019;33(4):560–7.
doi:10.1037/neu0000516.
24. Permenter CM, Fernández-de Thomas RJ, Sherman A. Postconcussive Syndrome. In: Treasure Island
(FL); 2020.
25. Berger A, Horst F, Müller S, Steinberg F, Doppelmayr M. Current State and Future Prospects of EEG
and fNIRS in Robot-Assisted Gait Rehabilitation: A Brief Review. Front Hum Neurosci. 2019;13:172.
Page 13/15
doi:10.3389/fnhum.2019.00172.
26. Thorpe ER, Garrett KB, Smith AM, Reneker JC, Phillips RS. Outcome Measure Scores Predict
Discharge Destination in Patients With Acute and Subacute Stroke: A Systematic Review and Series
of Meta-analyses. J Neurol Phys Ther. 2018;42(1):2–11. doi:10.1097/NPT.0000000000000211.
27. Tomida K, Sonoda S, Hirano S, et al. Randomized Controlled Trial of Gait Training Using Gait Exercise
Assist Robot (GEAR) in Stroke Patients with Hemiplegia. J stroke Cerebrovasc Dis Off J Natl Stroke
Assoc. 2019;28(9):2421–8. doi:10.1016/j.jstrokecerebrovasdis.2019.06.030.
28. Logan LM, Semrau JA, Debert CT, Kenzie JM, Scott SH, Dukelow SP. Using Robotics to Quantify
Impairments in Sensorimotor Ability, Visuospatial Attention, Working Memory, and Executive
Function After Traumatic Brain Injury. J Head Trauma Rehabil. 2018;33(4):E61–73.
doi:10.1097/HTR.0000000000000349.
29. Maggio MG, Torrisi M, Buda A, et al. Effects of robotic neurorehabilitation through lokomat plus
virtual reality on cognitive function in patients with traumatic brain injury: A retrospective case-
control study. Int J Neurosci. 2020;130(2):117–23. doi:10.1080/00207454.2019.1664519.
30. Esquenazi A, Lee S, Packel AT, Braitman L. A randomized comparative study of manually assisted
versus robotic-assisted body weight supported treadmill training in persons with a traumatic brain
injury. PM R. 2013;5(4):280–90. doi:10.1016/j.pmrj.2012.10.009.
31. Lapitskaya N, Nielsen JF, Fuglsang-Frederiksen A. Robotic gait training in patients with impaired
consciousness due to severe traumatic brain injury. Brain Inj. 2011;25(11):1070–9.
doi:10.3109/02699052.2011.607782.
32. Esquenazi A, Lee S, Wikoff A, Packel A, Toczylowski T, Feeley J. A Comparison of Locomotor Therapy
Interventions: Partial-Body Weight-Supported Treadmill, Lokomat, and G-EO Training in People With
Traumatic Brain Injury. PM R. 2017;9(9):839–46. doi:10.1016/j.pmrj.2016.12.010.
33. Kumar RG, Ketchum JM, Corrigan JD, Hammond FM, Sevigny M, Dams-O’Connor K. The Longitudinal
Effects of Comorbid Health Burden on Functional Outcomes for Adults With Moderate to Severe
Traumatic Brain Injury. J Head Trauma Rehabil. February 2020.
doi:10.1097/HTR.0000000000000572.
34. Louie DR, Mortenson WB, Durocher M, Teasell R, Yao J, Eng JJ. Exoskeleton for post-stroke recovery
of ambulation (ExStRA): Study protocol for a mixed-methods study investigating the e cacy and
acceptance of an exoskeleton-based physical therapy program during stroke inpatient rehabilitation.
BMC Neurol. 2020;20(1):1–9. doi:10.1186/s12883-020-1617-7.
Tables
Page 14/15
Table 1:  Demographic characteristics and exoskeleton use
Variable All subjects CVA TBI P-value
n (%) 77 (100) 66 (86) 11 (14) --
Age in years, mean (SD) 60.2 (16.3) 62.7 (12.8) 45 (25.8) 0.048
Hispanic/Latino, n (%) 73 (95) 62 (94) 11 (100) 0.402
Sex, n (%)        
      Males 60 (78) 51 (77.3) 9 (81.8) 0.999
      Females 17 (22) 15 (22.7) 2 (18.2)  
EKSO sessions, mean (SD) 3.3 (2.8) 3.3 (2.9) 3.5 (1.9) 0.767
EKSO minutes, mean (SD) 32.2 (35.25) 31 (35.4) 39.4 (34.9) 0.467
EKSO steps, mean (SD) 854.8 (944.1) 821.2 (946.2) 1056.6 (950.49) 0.448
LOS in days, mean (SD) 20.9 (8.77) 21.1 (9.2) 19.5 (5.5) 0.588
LOS e ciency, mean (SD) 1.8 (0.9) 1.8 (0.9) 2 (0.7) 0.414
EKSO: EKSO GT robotic exoskeleton; LOS: length of stay; LOS e ciency refers to the points increase in




Table 2:  Functional independence measure scores (FIM) before and after
exoskeleton use.
 
Variable,  mean (SD) All subjects CVA TBI P-
value
Admission overall score   41.9 (16.3) 42.3 (16.4) 39.5 (16.5) 0.598
Discharge overall score 74.6 (21.6) 74.3 (22.0) 76.9 (19.3) 0.709
Change in overall score 32.7 (13.2) 32.0 (13.4) 37.5 (11.6) 0.203
Change in motor score 23.5 (10.0) 22.9 (10.0) 27.4 (9.4) 0.177
Cognitive domain scores        
     Change in social interaction  1.4 (1.0) 1.4 (1.0) 1.3 (0.9) 0.683
     Change in problem solving 1.4 (1.0) 1.4 (1.1) 1.5 (0.8) 0.608
     Change in memory 1.5 (1.0) 1.5 (1.0) 1.6 (0.7) 0.673
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